FDA Tags Cipla Arm Sitec Labs’ Navi Mumbai Unit As ‘Voluntary Action Indicated’

The US Food and Drug Administration has classified Cipla Ltd.’s wholly-owned subsidiary, Sitec Labs Ltd.’s Navi Mumbai unit, as “voluntary action indicated.”

The regulatory body conducted a good manufacturing practices inspection at the Mahape-based analytical testing facility from February 18 to 20, Cipla said in an exchange filing late Saturday.